8-K: Moleculin Biotech Gears Up for Pivotal AML Trial, Anticipates Key Data Readout in 2025

Moleculin Biotech is progressing towards the launch of its MIRACLE pivotal study for relapsed/refractory AML, with the first patient expected to be treated this quarter and a key data readout anticipated by year-end.

Summary

• Moleculin Biotech is preparing to launch its MIRACLE pivotal study for the treatment of second-line relapsed/refractory Acute Myeloid Leukemia (AML).
• The trial is designed for new drug approval by the FDA and equivalent authorities globally, requiring FDA-audited clinical sites and a global contract research organization (CRO).
• Over 25 sites have been selected, with expectations to reach over 70 active sites.
• The first patient is expected to be treated this quarter, with drug distribution depots being set up globally.
• The company has amended its trial protocol based on FDA guidance and has IRB approval in the US.
• Moleculin anticipates unblinded data from the first 45 patients by the end of 2025 and completion of the 90-patient Part A of the trial by the first half of 2026.
• Meetings with over 30 investigators in 11 countries have shown strong support for Annamycin, with many acknowledging its potential to fill a significant unmet need for AML patients.
• Annamycin has shown promising preliminary results compared to Kura Oncology's targeted therapy in relapsed or refractory Venetoclax-treated patients, with a 60% CRc rate and 40% CR rate versus Kura's 36% CRc rate.
• The company is experiencing increased inbound interest from potential partners, with the 45-patient data readout seen as a potential pivot point.
• Moleculin believes that Annamycin has the potential to help more AML patients than all targeted therapies combined.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with strong investigator support, promising preliminary data, and increased partner interest. The company is on track with its trial preparations and anticipates key data readouts in the near future.

Positives

• The MIRACLE pivotal study is progressing well with site selection and preparations.
• There is strong investigator support for Annamycin, recognizing its potential to address unmet needs in AML.
• Annamycin has shown promising preliminary efficacy data compared to a competitor's targeted therapy.
• The company is experiencing increased interest from potential partners.
• The company expects to have unblinded data from the first 45 patients by the end of 2025.

Negatives

• Some investigators view the control arm of the trial as a challenge, preferring all patients receive Annamycin.
• The Kura Oncology data, while showing a 36% CRc rate, did not report a CR rate, which is a more important measure of efficacy.
• Both the Kura data and Moleculin's previous trial data are based on small sample sizes and should be considered preliminary.

Risks

• The trial requires working with FDA-audited clinical sites and a global CRO, which adds complexity.
• The CTIS process in the EU requires lead time and paperwork.
• The company needs to obtain individual institutional ethics committee signoffs and negotiate hospital contracts in the US.
• The trial is a blinded, randomized trial, which means some patients will not receive Annamycin.
• The preliminary data from both Moleculin and Kura are based on small sample sizes and may not be indicative of future results.

Future Outlook

Moleculin expects the first patient to be treated in the first quarter of 2025, with unblinded data from the first 45 patients expected by the end of 2025 and completion of the 90-patient Part A of the trial by the first half of 2026. The company anticipates significant progress in 2025.

Management Comments

• Wally Klemp stated that the MIRACLE trial is intended for new drug approval by the FDA and equivalent authorities.
• Wally Klemp mentioned that meetings with investigators have increased confidence in achieving recruitment goals.
• Wally Klemp noted that Annamycin is outperforming Kura's targeted therapy based on preliminary data.
• Wally Klemp believes that the 45-patient data readout could be a pivot point for potential partners.
• Wally Klemp stated that Annamycin is in a position to help more AML patients than all of the targeted therapies combined.

Industry Context

The announcement highlights the ongoing challenges in AML treatment and the potential for Annamycin to address unmet needs, particularly in patients who have relapsed or are refractory to existing therapies like Venetoclax. The comparison to Kura Oncology's targeted therapy underscores the competitive landscape and the importance of efficacy data in this space.

Comparison to Industry Standards

• Kura Oncology reported a CRc rate of 36% in relapsed or non-responsive Venetoclax patients, which was not on an intent-to-treat basis and did not report a CR rate.
• Moleculin reported a 60% CRc rate and a 40% CR rate in a similar patient population in a previous trial, on an intent-to-treat basis.
• Venetoclax, a non-targeted chemotherapy, has generated billions in revenue for AbbVie, highlighting the market potential for effective AML treatments.
• The market cap of Kura Oncology is close to a billion dollars, despite a recent drop after a partnering deal, indicating the high value placed on AML therapies.

Stakeholder Impact

• Shareholders can expect updates on the progress of the MIRACLE trial and potential partnership opportunities.
• Patients with relapsed/refractory AML may benefit from the development of Annamycin.
• Employees are involved in the execution of the clinical trial and related activities.
• Potential partners may be interested in the company's progress and data.

Next Steps

• The first patient is expected to be treated in the MIRACLE study this quarter.
• The company will continue to set up drug distribution depots globally.
• The company will continue to work on CTIS application approvals in the EU.
• The company will continue to finalize contracts in the US.
• The company expects to have unblinded data from the first 45 patients by the end of 2025.
• The company expects to complete the 90-patient Part A of the trial by the first half of 2026.

Key Dates

Keywords

Annamycin, AML, MIRACLE study, pivotal trial, clinical trial, FDA, relapsed/refractory, Venetoclax, Kura Oncology, targeted therapy, CRO, CRc, CR